Because the p53-mediated antiviral pathway is involved in host defense against a wide variety of viruses, TP53 gene therapy via SGT-53 has the potential of controlling viral infections against the various variants of SARS-CoV-2 that have emerged or will emerge in the course of the COVID-19 pandemic. This evidence concerns the gene SGTA and viral infectious disease.